Press Release

<< Back
View printer-friendly version

Spark Therapeutics Announces J.P. Morgan Healthcare Conference Participation

PHILADELPHIA, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that Jeffrey D. Marrazzo, co-founder and chief executive officer, is presenting at the J.P. Morgan 34th Annual Healthcare Conference on Monday, January 11, 2016 at 4:30 pm (PST), at the Westin St. Francis Hotel, San Francisco, California.

To access the slide deck presented, please visit the "Investor Presentations" section of the Spark Therapeutics website. A recording of Spark's presentation also will be available on Spark's website for 90 days following the conference. To access the recording, please visit the "Past Events" section within the "Events" section of the Spark Therapeutics website at www.sparktx.com.

About Spark Therapeutics
Spark is a gene therapy leader seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s initial focus is on treating rare diseases where no, or only palliative, therapies exist. Spark’s most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, recently reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark’s validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Spark builds on two decades of research, development and manufacturing at The Children’s Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of administration. To learn more, please visit www.sparktx.com.

Contacts

Investor Relations
Spark Therapeutics, Inc.Stephen W. Webster
Chief Financial Officer
(855) SPARKTX (1-855-772-7589)

Media
Ten Bridge CommunicationsDan Quinn
(781) 475-7974
dan@tenbridgecommunications.com

Primary Logo

Spark Therapeutics, Inc.